跳至主要内容
临床试验/ACTRN12610000080022
ACTRN12610000080022尚未招募3 期

A randomised placebo crossover trial to compare the effects of nebulised salbutamol and ipratropium driven by air and oxygen on transcutaneous crabon dioxide (CO2) levels in patients with severe Chronic Obstructive Pulmonary Disease (COPD).

Medical Research Institute of New Zealand (MRINZ)0 个研究点目标入组 18 人开始时间: 2010年1月22日最近更新:
适应症

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Diagnosis of COPD according to British Thoracic Society (BTS) criteria
  • Pre-bronchodilator forced expiratory volume in 1 second (FEV1) less than or equal to 40% of predicted

排除标准

  • History of allergy/sensitivity to study drugs
  • On warfarin
  • Concurrent risk factors for hypercapnic respiratory failure (Body Mass Index >40, chest wall restriction, severe musculoskeletal weakness)
  • Those needing >4L oxygen via nasal cannulae to keep saturations >88%

研究者

发起方
Medical Research Institute of New Zealand (MRINZ)

相似试验

A randomised trial of air and oxygen driven... | 临床试验